Moderna (MRNA) Competitors $26.83 -0.70 (-2.54%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$27.16 +0.33 (+1.21%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, REGN, TSLA, JNJ, MRK, and PFEShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Regeneron Pharmaceuticals (REGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), and Pfizer (PFE). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Regeneron Pharmaceuticals Tesla Johnson & Johnson Merck & Co., Inc. Pfizer Moderna (NASDAQ:MRNA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends. Is MRNA or CRSP more profitable? Moderna has a net margin of -94.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Do insiders & institutionals believe in MRNA or CRSP? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, MRNA or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.24-$3.56B-$7.53-3.56CRISPR Therapeutics$35M189.88-$366.25M-$5.43-13.46 Does the media favor MRNA or CRSP? In the previous week, Moderna had 2 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 18 mentions for Moderna and 16 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.88 beat Moderna's score of 0.54 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 5 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MRNA or CRSP? Moderna currently has a consensus price target of $41.81, indicating a potential upside of 55.84%. CRISPR Therapeutics has a consensus price target of $71.50, indicating a potential downside of 2.15%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 5 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.00CRISPR Therapeutics 2 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.42 Which has more volatility and risk, MRNA or CRSP? Moderna has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. SummaryModerna beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.48B$3.33B$6.05B$10.24BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-3.5622.2586.4726.55Price / Sales3.24465.52615.33192.34Price / CashN/A44.9825.7330.17Price / Book0.9510.2112.656.52Net Income-$3.56B-$52.40M$3.31B$276.31M7 Day Performance-2.58%0.20%-0.74%-2.92%1 Month Performance14.12%13.49%8.31%4.14%1 Year Performance-53.97%27.29%76.21%30.13% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.221 of 5 stars$26.83-2.5%$41.81+55.8%-54.0%$10.48B$3.06B-3.565,800Analyst ForecastCRSPCRISPR Therapeutics1.6655 of 5 stars$70.74+4.4%$71.50+1.1%+56.0%$6.45B$37.31M-13.07460Analyst ForecastCVACCureVac3.7035 of 5 stars$5.41-0.8%$6.83+26.4%+84.9%$1.21B$579.18M5.63880HOODRobinhood Markets3.0313 of 5 stars$148.10-0.4%$113.59-23.3%+429.0%$131.46B$2.95B75.092,300Trending NewsNVAXNovavax4.2116 of 5 stars$9.32-1.5%$14.29+53.3%-33.5%$1.52B$1.08B4.101,990OCGNOcugen1.4732 of 5 stars$1.78+0.3%$6.00+238.0%+73.6%$515.91M$4.05M-8.8280REGNRegeneron Pharmaceuticals4.7317 of 5 stars$591.85-1.4%$817.67+38.2%-44.4%$62.71B$14.21B14.9115,106Positive NewsAnalyst ForecastAnalyst RevisionTSLATesla3.9353 of 5 stars$448.77+4.4%$344.40-23.3%+89.8%$1.49T$97.69B259.12125,665Trending NewsAnalyst ForecastJNJJohnson & Johnson4.6654 of 5 stars$188.26-0.2%$189.12+0.5%+18.1%$453.40B$90.63B20.14138,100Trending NewsUpcoming EarningsAnalyst ForecastMRKMerck & Co., Inc.4.9927 of 5 stars$88.98-0.2%$106.41+19.6%-21.6%$222.28B$64.17B13.7175,000Trending NewsAnalyst RevisionPFEPfizer4.9535 of 5 stars$26.91-1.7%$28.41+5.6%-14.9%$153.03B$63.83B14.3281,000Positive NewsDividend AnnouncementAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Regeneron Pharmaceuticals Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
